--- title: "Bausch Health Companies (BHC) news: offering and merger" url: "https://aibio.space/companies/bausch-health-companies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BHC offering and merger news: Bausch Health launches $4.0 billion senior secured notes offering to refinance debt. Bausch Health Companies Inc." --- BHC Bausch Health Companies Inc. TSX · Canada # Bausch Health Companies (BHC) news BHC offering and merger news Mergers · 2025-09-11 ## [Bausch Health completes DURECT acquisition after tender offer draws about 62% of shares](https://aibio.space/news/bausch-health-completes-durect-acquisition-after-tender-offer-draws/) BHC Lyon accepted 19,984,767 DURECT shares and merged into DURECT on September 11, 2025. Holders get $1.75 per share in cash plus a contingent value right that pays only if net sales milestones are reached. ## Latest Bausch Health Companies news 1. 2025-03-19 Mergers [Bausch Health launches $4.0 billion senior secured notes offering to refinance debt](https://aibio.space/news/bausch-health-launches-4-0-billion-senior-secured-notes-offering/) Bausch Health's subsidiary launched a $4.0 billion offering of senior secured notes due 2032, and the parent began syndicating new secured credit facilities. The proceeds would retire 2025 and 2027 debt, but the filing gives no interest rate on the new notes or the term loan. ## Bausch Health Companies at a glance - **Ticker**: BHC - **Listing**: TSX - **Country**: Canada - **Cash, Sep 30, 2026**: $2.48 billion ### Related companies - [Cipher Pharmaceuticals](https://aibio.space/companies/cipher-pharmaceuticals/) TSX: CPH - [Pharmadrug](https://aibio.space/companies/pharmadrug/) CSE: PHRX - [Noveris Health Sciences](https://aibio.space/companies/noveris-health-sciences/) CSE: NVRS - [Restart Life Sciences](https://aibio.space/companies/restart-life-sciences/) CSE: HEAL - [CanaQuest Medical](https://aibio.space/companies/canaquest-medical/) OTC: CANQF - [Neural Therapeutics](https://aibio.space/companies/neural-therapeutics/) CSE: NURL - [LIR Life Sciences](https://aibio.space/companies/lir-life-sciences/) CSE: SKNY - [Modern Mobility Aids](https://aibio.space/companies/modern-mobility-aids/) OTC: MDRM ### Also on TSX - [Satellos Bioscience](https://aibio.space/companies/satellos-bioscience/) MSCL - [Apotex Health](https://aibio.space/companies/apotex-health/) APTX - [Medexus Pharmaceuticals](https://aibio.space/companies/medexus-pharmaceuticals/) MDP - [Medicenna Therapeutics](https://aibio.space/companies/medicenna-therapeutics/) MDNA - [Resverlogix](https://aibio.space/companies/resverlogix/) RVX - [Knight Therapeutics](https://aibio.space/companies/knight-therapeutics/) GUD ## What Bausch Health Companies does Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. It develops, manufactures and markets branded, generic and branded generic pharmaceuticals, over-the-counter products and aesthetic medical devices, primarily in gastroenterology, hepatology, neurology and dermatology. Through its approximately 88% ownership of Bausch + Lomb Corporation, it also markets eye health products. Its products are marketed in approximately 90 countries and fall into five reportable segments: Salix, International, Solta Medical, Diversified and Bausch + Lomb. Its Xifaxan product line, indicated for irritable bowel syndrome with diarrhea and for reducing the risk of overt hepatic encephalopathy recurrence, represents approximately 85% of Salix segment revenues. Other principal products include Relistor, for constipation in adults using narcotic medicine for chronic pain, and Trulance, a once-daily tablet for chronic idiopathic constipation. Revenues were $10,266 million in 2025, and the company has approximately 1,000 products in its portfolio. | Product or program | What it is | Stage | |---|---|---| | Xifaxan | Tablets for IBS-D, hepatic encephalopathy recurrence and travelers' diarrhea | | | Relistor (methylnaltrexone) | Prevents constipation in adults using narcotic medicine for chronic pain | | | Trulance (plecanatide) | Once-daily tablet for chronic idiopathic constipation | | Summarised from the company's [10-K filed Feb 19, 2026](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/bhc-20251231.htm). ## Bausch Health Companies annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$629.0 million](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | [$616.0 million](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | | Net income (loss) | [$157.0 million](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | [-$46.0 million](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | | Cash from operations | [$1.40 billion](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | [$1.60 billion](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | | Cash and equivalents | [$1.31 billion](https://www.sec.gov/Archives/edgar/data/885590/000088559026000123/) | [$1.18 billion](https://www.sec.gov/Archives/edgar/data/885590/000088559026000023/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $2.48 billion. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Bausch Health Companies Has Bausch Health Companies raised money recently? Our latest story on this, dated Mar 19, 2025: "Bausch Health launches $4.0 billion senior secured notes offering to refinance debt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bausch-health-launches-4-0-billion-senior-secured-notes-offering/). Is Bausch Health Companies involved in a merger or acquisition? Our latest story on this, dated Sep 11, 2025: "Bausch Health completes DURECT acquisition after tender offer draws about 62% of shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bausch-health-completes-durect-acquisition-after-tender-offer-draws/). What is the ticker symbol of Bausch Health Companies? Bausch Health Companies Inc. trades under the ticker BHC on TSX. Where is Bausch Health Companies listed? Bausch Health Companies Inc. is listed on TSX. Our directory also records these other listings: BMV:BHC/N; GETTEX:BVF; LSX:A2JQ1X; NEO:BHC; NYSE:BHC. What is the SEC CIK of Bausch Health Companies? The SEC Central Index Key (CIK) for Bausch Health Companies Inc. is 885590. Its filings are on SEC EDGAR. How many shares does Bausch Health Companies have outstanding? 373,990,561 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-30. Which country or territory is Bausch Health Companies listed under? Our directory records Bausch Health Companies Inc. under Canada. What does Bausch Health Companies do? Our directory classifies Bausch Health Companies Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Bausch Health Companies? The ISIN recorded for Bausch Health Companies Inc. is CA0717341071. Does aibio.space cover Bausch Health Companies? aibio.space lists Bausch Health Companies Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Bausch Health Companies incorporated? SEC records list its state or country of incorporation as NJ. What does Bausch Health Companies develop? Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. It develops, manufactures and markets branded, generic and branded generic pharmaceuticals, over-the-counter products and aesthetic medical devices, primarily in gastroenterology, hepatology, neurology and dermatology. What is Xifaxan from Bausch Health Companies? Xifaxan: Tablets for IBS-D, hepatic encephalopathy recurrence and travelers' diarrhea What is Relistor (methylnaltrexone) from Bausch Health Companies? Relistor (methylnaltrexone): Prevents constipation in adults using narcotic medicine for chronic pain Is Bausch Health Companies profitable? Bausch Health Companies Inc. reported net income of $157.0 million for the fiscal year ended Dec 31, 2025, and generated $1.40 billion of cash from operations, per its annual report to the SEC. ## Investor discussion: Bausch Health Companies Members talk about Bausch Health Companies (BHC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Bausch Health Companies, newest first. Each line links the filing it comes from. 1. 2026-04-30 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/885590/000088559026000053/bhc-20260331.htm) 2. 2025-08-15 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/885590/000119312525181736/d858618dex991.htm) 3. 2025-07-29 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/885590/000119312525167131/d943437dex991.htm) 4. 2025-05-01 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/885590/000088559025000020/bhc-20250331.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TSX:BHC on TradingView](https://www.tradingview.com/symbols/TSX-BHC/). ## SEC filings and registration - **SEC name**: Bausch Health Companies Inc. - **CIK**: 885590 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BHC (NYSE) - **State or country of incorporation**: NJ - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 2150 ST. ELZEAR BLVD. WEST, QUEBEC, Quebec, Canada, H7L 4A8 - **Phone**: 514-744-6792 - **Shares outstanding**: 373,990,561 as of 2026-07-24 (10-Q filed 2026-07-30) - **Former names**: Valeant Pharmaceuticals International, Inc.; BIOVAIL Corp; BIOVAIL CORP INTERNATIONAL ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/885590/000088559026000107/bhc-20260630.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/885590/000088559026000105/bhc-20260729.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/885590/000088559026000089/bhc-20260626.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/885590/000088559026000057/bhc-20260519.htm) filed 2026-05-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/885590/000088559026000053/bhc-20260331.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/885590/000088559026000051/bhc-20260429.htm) filed 2026-04-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/885590/000114036126013816/ny20055690x1_def14a.htm) filed 2026-04-08 - [8-K](https://www.sec.gov/Archives/edgar/data/885590/000119312526085755/d938319d8k.htm) filed 2026-03-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000885590), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Bausch Health Companies Inc. is a public biotech or pharmaceutical company listed on TSX under the ticker BHC, recorded under Canada. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Bausch Health Companies Inc. - **Ticker**: BHC - **Listing**: TSX - **Country or territory**: Canada - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: CA0717341071 - **Other listed symbols**: BMV:BHC/N; GETTEX:BVF; LSX:A2JQ1X; NEO:BHC; NYSE:BHC - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/TSX-BHC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bausch-health-companies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bausch Health Companies (BHC) news: offering and merger", 2026-10-31, https://aibio.space/companies/bausch-health-companies/